Metamizol +pharma (Metamizole Sodium Monohydrate)

Metamizole sodium exerts its effect by non‑selectively inhibiting cyclooxygenase enzymes, which lowers prostaglandin production and reduces inflammation. It also influences central pain pathways in the spinal cord and brain, providing additional analgesic and antipyretic actions.

The appropriate dose of Metamizol +pharma is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal function. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety data for Metamizole sodium in pregnancy and lactation are limited. Because of potential risks such as agranulocytosis, it is generally avoided unless the benefit clearly outweighs the risk and no safer alternative is available. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional NSAIDs such as ibuprofen, Metamizol offers strong analgesic and antipyretic effects with a lower incidence of gastric irritation but carries a unique risk of severe blood dyscrasias like agranulocytosis. Choice of therapy should balance efficacy, safety profile, and patient‑specific factors.

Store Metamizol +pharma at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain its stability and potency.

Metamizol +pharma is administered orally. The tablet or oral formulation should be swallowed whole with a glass of water, unless otherwise directed by a healthcare professional.

The most serious adverse events include agranulocytosis, which can lead to severe infections, and life‑threatening hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Prompt medical attention is required if symptoms of these conditions appear.

Metamizol +pharma should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, patients with existing blood dyscrasias, severe liver disease, or those currently receiving other bone‑marrow suppressive therapies. Use in children is generally contraindicated unless specifically approved.